Online Relapse Prevention Study (ORP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04862247|
Recruitment Status : Recruiting
First Posted : April 27, 2021
Last Update Posted : April 11, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Eating Disorders Anorexia Nervosa Bulimia Nervosa Anorexia Nervosa, Atypical Other Specified Feeding or Eating Disorder||Behavioral: Imaginal Exposure Condition Behavioral: Writing and Thinking Condition||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||130 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Randomized Control Trial of a Relapse Prevention Online Exposure Protocol for Eating Disorders and Mechanisms of Change|
|Actual Study Start Date :||June 4, 2021|
|Estimated Primary Completion Date :||June 1, 2023|
|Estimated Study Completion Date :||December 1, 2023|
Experimental: Imaginal Exposure Condition
Participants will complete one phone session including education about the treatment followed by four online sessions of imaginal exposure across a one month time period. Each session is separated by 1 week.
Behavioral: Imaginal Exposure Condition
Participants will be asked to think and write about an eating related fear or anxiety. Specifically, they will be asked to spend 20-30 minutes writing about a specific fear or anxiety they have, then another 20-35 minutes re-reading and imagining that what they have written is happening.
Active Comparator: Writing and Thinking Condition
Participants will complete one phone session including education about the treatment followed by four online sessions of a writing and thinking intervention across a one month time period. Each session is separated by 1 week.
Behavioral: Writing and Thinking Condition
Participants will be asked to think and write about their eating disorder using specific prompts designed to help them process their eating disorder. Specifically, they will be asked to spend 20-30 minutes writing their eating disorder, then another 20-35 minutes re-reading what they wrote.
- Rate of Eating Disorder Relapse [ Time Frame: 6-Month Follow-Up ]First, the investigators will define relapse as moving from one stage of remission to another (e.g., remission to partial remission or partial remission to currently ill). Second, the investigators will define relapse as re-entry into a more intensive treatment setting (e.g., moving from outpatient to partial hospitalization).
- Change in Eating Disorder Symptoms using the EDE-Q [ Time Frame: Up to 6-Month Follow-Up ]The Eating Disorder Examination Questionnaire (EDEQ), a self-reported measure, is assessed at multiple time points throughout the duration of the study and is used to examine the attitudes and behaviors in individuals with eating disorder symptoms.
- Re-admission Percentage [ Time Frame: 1 Month Follow Up and 6 Month Follow Up ]Using the Treatment Interview, we will assess all current and past treatment experiences, dates of treatment, and primary type of treatment. Re-admission will be assessed at follow up timepoints and defined as re-entry into a more intensive treatment setting.
- Change in State Anxiety [ Time Frame: Treatment Session 1 through 5 ]Subjective Units of Distress(SUDS) is a valid and reliable behavioral measure of state anxiety used during each treatment session to measure anxiety and distress and will be collected before, during, and after each session. Additionally, the Brief State Anxiety Measure is a 6-item measure with acceptable reliability and validity and sensitivity to fluctuations in state anxiety levels and will be collected at the beginning and end of each session.
- Change in State Fear of Food [ Time Frame: Treatment Session 2 through 5 ]State Fear of Food Measure will be used to assess food anxiety, food avoidance, and feared concerns and will be collected at the beginning and end of each session.
- Change in Positive and Negative Affect [ Time Frame: Treatment Session 2 through 5 ]State Positive and Negative Affect Schedule will be used to assess positive and negative affect at the beginning and end of each session.
- Change in Eating Disorder Symptoms [ Time Frame: Treatment Session 2 through 5 ]Eating Disorder-15 is a 15-item measure of eating disorder cognitions and behaviors, which will be collected at the beginning of each treatment session.
- Fear Extinction [ Time Frame: Up to 6 Month Follow Up ]FLARe is a validated smart-phone behavioral assessment of fear learning that will assess target engagement at baseline, post, and one and six month follow-ups.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- over the age of 18
- discharged from intensive treatment within the last month (inpatient, residential, partial hospital/day program, intensive outpatient program)
- currently meet criteria for anorexia nervosa, other specified feeding and eating disorder-atypical anorexia nervosa, or bulimia nervosa
- high and active suicidality, psychosis, mania, or medical compromised status will be excluded, as these comorbidities would make it difficult to complete study procedures
- under the age of 18
- does not meet criteria for anorexia nervosa, other specified feeding and eating disorder-atypical anorexia nervosa, or bulimia nervosa.
- discharged from intensive treatment more than a month ago
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04862247
|Contact: Cheri A Levinson, PhDfirstname.lastname@example.org|
|Contact: Taylor E Gardner, B.A.||email@example.com|
|United States, Kentucky|
|Eating Anxiety Treatment Laboratory and Clinic||Recruiting|
|Louisville, Kentucky, United States, 40292|
|Contact: Cheri A Levinson, PhD|
|Principal Investigator:||Cheri A Levinson, PhD||University of Louisville|
|Responsible Party:||Cheri Levinson, Director, University of Louisville|
|Other Study ID Numbers:||
1R34MH124799-01 ( U.S. NIH Grant/Contract )
|First Posted:||April 27, 2021 Key Record Dates|
|Last Update Posted:||April 11, 2022|
|Last Verified:||April 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Eating Disorder Symptoms
Feeding and Eating Disorders
Signs and Symptoms, Digestive